Citadel Advisors’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$81.1M Buy
323,587
+77,947
+32% +$19.4M 0.01% 959
2025
Q4
$67.6M Sell
245,640
-481,897
-66% -$132M 0.01% 1145
2025
Q3
$191M Buy
727,537
+598,751
+465% +$146M 0.03% 496
2025
Q2
$28.2M Sell
128,786
-151,941
-54% -$32.5M ﹤0.01% 1753
2025
Q1
$62.8M Sell
280,727
-390,151
-58% -$108M 0.01% 982
2024
Q4
$220M Buy
670,878
+622,752
+1,294% +$196M 0.04% 375
2024
Q3
$14.4M Sell
48,126
-232,218
-83% -$71.1M ﹤0.01% 2425
2024
Q2
$92.3M Sell
280,344
-779,802
-74% -$276M 0.02% 732
2024
Q1
$420M Buy
1,060,146
+131,129
+14% +$48.5M 0.08% 161
2023
Q4
$327M Sell
929,017
-622,761
-40% -$220M 0.07% 197
2023
Q3
$582M Buy
1,551,778
+498,447
+47% +$193M 0.12% 83
2023
Q2
$403M Sell
1,053,331
-45,851
-4% -$16.4M 0.08% 119
2023
Q1
$381M Buy
1,099,182
+938,098
+582% +$274M 0.08% 139
2022
Q4
$37.9M Sell
161,084
-55,815
-26% -$13.2M 0.01% 1345
2022
Q3
$53.4M Buy
216,899
+81,966
+61% +$25M 0.01% 1014
2022
Q2
$40.8M Sell
134,933
-260,198
-66% -$84.7M 0.01% 1179
2022
Q1
$162M Buy
395,131
+394,115
+38,791% +$154M 0.03% 431
2021
Q4
$477K Sell
1,016
-54,943
-98% -$23.6M ﹤0.01% 9813
2021
Q3
$23.8M Buy
55,959
+28,271
+102% +$11.9M ﹤0.01% 1813
2021
Q2
$9.94M Buy
+27,688
New +$9.15M ﹤0.01% 3086
2021
Q1
Sell
-16,711
Closed -$4.78M 13786
2020
Q4
$4.73M Buy
16,711
+11,541
+223% +$3.24M ﹤0.01% 3796
2020
Q3
$1.42M Sell
5,170
-135,855
-96% -$36M ﹤0.01% 5375
2020
Q2
$32M Buy
141,025
+128,809
+1,054% +$25.3M 0.01% 1112
2020
Q1
$1.86M Sell
12,216
-23,052
-65% -$3.55M ﹤0.01% 4265
2019
Q4
$5.3M Sell
35,268
-93,193
-73% -$13.6M ﹤0.01% 3007
2019
Q3
$18.2M Buy
128,461
+66,639
+108% +$9.18M 0.01% 1564
2019
Q2
$7.74M Buy
61,822
+49,024
+383% +$5.79M ﹤0.01% 2503
2019
Q1
$1.41M Buy
12,798
+9,493
+287% +$987K ﹤0.01% 5006
2018
Q4
$324K Buy
3,305
+487
+17% +$52.8K ﹤0.01% 7119
2018
Q3
$348K Sell
2,818
-568
-17% -$63.7K ﹤0.01% 7336
2018
Q2
$336K Sell
3,386
-33,803
-91% -$3.11M ﹤0.01% 7019
2018
Q1
$3.28M Buy
37,189
+4,492
+14% +$420K ﹤0.01% 3015
2017
Q4
$3.23M Buy
32,697
+28,054
+604% +$2.75M ﹤0.01% 3007
2017
Q3
$447K Sell
4,643
-22,429
-83% -$2.03M ﹤0.01% 5485
2017
Q2
$2.56M Sell
27,072
-21,200
-44% -$1.95M ﹤0.01% 2854
2017
Q1
$3.94M Buy
48,272
+32,064
+198% +$2.68M ﹤0.01% 2284
2016
Q4
$1.38M Sell
16,208
-55,759
-77% -$4.38M ﹤0.01% 3410
2016
Q3
$5.36M Buy
+71,967
New +$5.71M 0.01% 1916
2016
Q2
Sell
-10,917
Closed -$757K 7486
2016
Q1
$757K Sell
10,917
-44,204
-80% -$2.66M ﹤0.01% 3826
2015
Q4
$3.32M Buy
55,121
+54,741
+14,406% +$3.29M ﹤0.01% 2210
2015
Q3
$21K Buy
+380
New +$22.1K ﹤0.01% 8130
2015
Q2
Sell
-10,010
Closed -$559K 9132
2015
Q1
$603K Buy
+10,010
New +$533K ﹤0.01% 4637
2014
Q4
Sell
-35,427
Closed -$1.58M 8762
2014
Q3
$1.58M Sell
35,427
-2,595
-7% -$110K ﹤0.01% 3131
2014
Q2
$1.6M Buy
38,022
+36,009
+1,789% +$1.54M ﹤0.01% 2954
2014
Q1
$89K Sell
2,013
-6,908
-77% -$325K ﹤0.01% 6311
2013
Q4
$438K Sell
8,921
-33,406
-79% -$1.56M ﹤0.01% 4176
2013
Q3
$1.74M Sell
42,327
-103,007
-71% -$3.93M ﹤0.01% 2547
2013
Q2
$5.11M Buy
+145,334
New +$4.78M 0.01% 1557

Other funds holding WST

Citadel Advisors's WST Position: Q1 2026 in Review

Citadel Advisors increased its West Pharmaceutical (WST) stake by 32% in Q1 2026, buying an estimated $19.4M and bringing the position to 323,587 shares worth $81.1M. The position accounts for 0.01% of the portfolio, ranked #959.

Citadel Advisors first reported a position in WST in Q2 2013 and has held it in 48 quarters since. The position peaked at $582M in Q3 2023. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Citadel Advisors held 323,587 shares of West Pharmaceutical worth $81.1M as of Q1 2026.
  • Citadel Advisors bought 77,947 West Pharmaceutical shares in Q1 2026, an estimated $19.4M.
  • West Pharmaceutical made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #959 holding.
  • Citadel Advisors first reported a position in West Pharmaceutical in Q2 2013 and has held it in 48 quarters since.
  • Citadel Advisors's West Pharmaceutical position peaked at $582M in Q3 2023.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.